Image courtesy of the University of Toronto
Researchers in the lab of Dr. David Lovejoy have been at the forefront of physiologically active peptide discovery for three decades. Protagenic Therapeutics is the fortunate beneficiary of the worldwide exclusive license to commercialize one of the most promising molecules to come out of the Lovejoy Lab, PT00014.
Over the last 20 years, research programs in the Lovejoy Laboratory have focused on the discovery and function of new peptide hormones that pertain to the physiology of stress, reproduction and energy metabolism. Building upon an academic research background on the discovery and evolution of gonadotropin-releasing hormone (GnRH) and corticotropin releasing factor (CRF) peptide families, the Laboratory subsequently developed methods to predict the existence of new peptide families. This work led to the discovery of the teneurin C-terminal associated peptides (TCAP), a family of peptides that play a major role in energy regulation and are found in all animals. The physiological importance of these peptides and their practical applications led to the co-founding of Protagenic Therapeutics. As a result, the Laboratory is now based around the primary applications of TCAP and their role in the human condition. Currently, we are now focusing on the molecular mechanisms by which TCAP achieves its actions and have subsequently developed new methods to create new synthetic variants of TCAP for the treatment of neurological and metabolism associated disorders. This work is expected to lead to new patent applications to assist Protagenic Therapeutics in our strategic development as well as develop a new understanding of the role of energy metabolism in neurological diseases.
Dr. Lovejoy is part of the Department of Cell and Systems Biology at the University of Toronto.